Pharmaceutical development focused on anti-psychotics, anti-depressant/anxiolytics, analgesics
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
32
NCT03817346
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 17, 2018
Completion: May 31, 2019
Loading map...